Optimizing disease progression study designs for drug effect discrimination

Author： Ueckert Sebastian   Hennig Stefanie   Nyberg Joakim   Karlsson Mats   Hooker Andrew  

Publisher： Springer Publishing Company

ISSN： 1567-567X

Source： Journal of Pharmacokinetics and Pharmacodynamics, Vol.40, Iss.5, 2013-10, pp. : 587-596

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Application of Clinical Trial Simulation to Compare Proof-of-Concept Study Designs for Drugs with a Slow Onset of Effect; An Example in Alzheimer's Disease

By Lockwood Peter   Ewy Wayne   Hermann David   Holford Nick  

Pharmaceutical Research, Vol. 23, Iss. 9, 2006-09 ,pp. : 2050-2059

Springer Publishing Company

Access to resources Recommend Favorite

Predictive Biomarkers for Linking Disease Pathology and Drug Effect

By  

Current Pharmaceutical Design, Vol. 23, Iss. 1, 2017-02 ,pp. : 29-54

Bentham Science Publishers

Access to resources Recommend Favorite

Cannabinoid-Opioid Interactions in Drug Discrimination and Self-Administration: Effect of Maternal, Postnatal, Adolescent and Adult Exposure to the Drugs

By  

Current Drug Targets, Vol. 11, Iss. 4, 2010-04 ,pp. : 450-461

Bentham Science Publishers

Access to resources Recommend Favorite

Disease progression and neuroscience

By Holford Nick  

Journal of Pharmacokinetics and Pharmacodynamics, Vol. 40, Iss. 3, 2013-06 ,pp. : 369-376

Springer Publishing Company

Access to resources Recommend Favorite

Targeting the Progression of Parkinson's Disease

By  

Current Neuropharmacology, Vol. 7, Iss. 1, 2009-03 ,pp. : 9-36

Bentham Science Publishers

Access to resources Recommend Favorite